Background: A unique opportunity to eradicate cancer is presented immediately after the excision of the primary tumor, but surgical procedures often induce the release of immunosuppressing factors that render cell mediated immunity ineffective. Here we tested the hypothesis that integration of peri-operative immunostimulation and blockade of immunosuppression could synergistically improve post-operative anti-metastatic immunity and long-term survival. Methods: Two syngeneic tumor models in F344 rats were employed, studying post-operative tumor progression. In the first model, survival following laparotomy and CRNK-16 leukemia was studied. Rats were peri-operatively treated with the immuno-stimulant poly I-C (5 Â 0.2 mg/kg/inj), with catecholamine-and prostaglandin-blockers (shown to prevent postoperative immunosuppression: 4.5 mg/kg nadolol, 4 mg/kg indomethacin), with both interventions, or with neither. Long-term survival was assessed thereafter. The second model used the MADB106 mammary adenocarcinoma, assessing its lung tumor retention (LTR) following i.v. inoculation, as well as host marginating-pulmonary NK numbers and activity against this tumor. IL-12 was employed for immunostimulation (4 Â 1.5 lg/kg/inj), with and without the above blockers. Results: Post-operative CRNK-16 survival rates were significantly improved only by the integrated approach of immune stimulation and endocrine blockers. Post-operative MADB106 LTR was additively reduced by the two interventions. Importantly, while IL-12 increased pulmonary NK cytotoxicity against MADB106, surgery markedly suppressed this cytotoxicity in both IL-12 and vehicle treated animals. The blockers prevented this suppression per lung and per single NK cell. Conclusions: Immunostimulation could be rendered ineffective postoperatively due to immunosuppression; therefore integrating endocrine-blocker therapies into the realm of peri-operative immunotherapy could optimize immune control over residual disease, potentially improving clinical outcomes.
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Introduction
The greatest threat to cancer patients is the recurrence of the disease, rather than the damage associated with the often removable primary tumor (Shakhar and Ben-Eliyahu, 2003) . Metastatic recurrence is most prevalent, and these malignant foci tend to be more aggressive, less reactive to therapy and often inoperable. Post-operative metastases develop from minimal residual disease (MRD), which is comprised of pre-existing micrometastases and scattered tumor cells left after the excision of the primary tumor. Unfortunately, the surgical removal of the primary tumor promotes the release of tumor emboli and induces temporary physiological conditions that favor the survival and progression of MRD (Eschwege et al., 1995; Folkman, 1995; Da Costa et al., 1998a,b; Yamaguchi et al., 2000; Lee et al., 2009) . To this end, the peri-operative period has been suggested to be critical for determining longterm recurrence rates, and presents an opportunity to improve clinical outcomes.
Immune stimulation has been studied in cancer patients for decades, and various approaches have been used to limit side effect and improve efficacy (for review see (Smyth et al., 2001; Del Vecchio et al., 2007) ). Among potential obstacles, immunosuppression induced by some tumors was reported to dampen the efficacy of immunostimulation. This has led to the realization that the context of immuno-stimulatory therapy is crucial, and some researchers study immunotherapy for eradicating MRD in the later post-operative context (for review see (Da Costa et al., 1998a,b) ).
However, the immediate post-operative period seems most critical for eradicating MRD before uncontrollable metastases are established (Shakhar and Ben-Eliyahu, 2003) . Unfortunately this period is often characterized by marked immunosuppression 0889-1591/$ -see front matter Ó 2010 Elsevier Inc. All rights reserved. doi:10.1016/j.bbi.2010.03.010
